39740-30-2

Usage

Uses

Used in Pharmaceutical Industry:
L-DOPA Ethyl Ester Hydrochloride is used as an active ingredient for the treatment of Parkinson's disease. It serves as a precursor to dopamine in the brain, helping to alleviate the symptoms of the disease by increasing the levels of dopamine, which is often deficient in Parkinson's patients.
L-DOPA Ethyl Ester Hydrochloride's off-white solid form and chemical properties make it suitable for formulation into various dosage forms, such as tablets or capsules, for easy administration to patients. Its role in Parkinson's disease treatment highlights its importance in the pharmaceutical industry as a key component in managing the condition.

Upstream product

• 64-17-5 ethanol 
• 59-92-7 3,4-dihydroxy-L-phenylalanine 
• 59-92-7 levodopa 

Downstream Products

• 128218-09-7 5--2,3-dihydro-8,9-bis(benzyloxy)-1H-pyrimido<1,2-a>quinoline-1-carboxylic acid tert-butyl ester 
• 128218-24-6 4-Amino-2-(6,7-bis-benzyloxy-3-tert-butoxycarbonylamino-2-oxo-3,4-dihydro-2H-quinolin-1-yl)-butyric acid tert-butyl ester 
• 128218-07-5 1-<1-(tert-Butoxycarbonyl)-3-<(tert-butoxycarbonyl)amino>propyl>-3-<(allyloxycarbonyl)amino>-6,7-bis(benzyloxy)tetrahydroquinolin-2-one 
• 128218-10-0 1-<1-(tert-Butoxycarbonyl)-3-<(tert-butoxycarbonyl)amino>propyl>-3-<(allyloxycarbonyl)amino>-6,7-bis(benzyloxy)tetrahydroquinoline-2-thione 
• 128217-89-0 2-(3-Allyloxycarbonylamino-6,7-bis-benzyloxy-2-oxo-3,4-dihydro-2H-quinolin-1-yl)-4-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-butyric acid tert-butyl ester 
• 128218-22-4 C₄₈H₅₁N₃O₁₁ 
• 3165-57-9 2-Amino-3-(3,4-dimethoxy-phenyl)-propionic acid ethyl ester 
• 128217-61-8 2-tert-Butoxycarbonylamino-3-(3,4-dimethoxy-phenyl)-propionic acid ethyl ester 
• 128217-65-2 2-Allyloxycarbonylamino-3-(3,4-dimethoxy-phenyl)-propionic acid ethyl ester 
• 69295-27-8 2-Amino-3-(3,4-bis-benzyloxy-phenyl)-propionic acid ethyl ester 
• 128217-76-5 2-Allyloxycarbonylamino-3-(4,5-dimethoxy-2-nitro-phenyl)-propionic acid ethyl ester 
• 128217-83-4 (6,7-Bis-benzyloxy-2-oxo-1,2,3,4-tetrahydro-quinolin-3-yl)-carbamic acid allyl ester 
• 128217-85-6 2-(6,7-Bis-benzyloxy-2-oxo-1,2,3,4-tetrahydro-quinolin-3-yl)-isoindole-1,3-dione 
• 128217-63-0 2-Allyloxycarbonylamino-3-(3,4-bis-benzyloxy-phenyl)-propionic acid ethyl ester 

Relevant academic research and scientific papers

NOVEL HIGH PENETRATION DRUGS AND COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON'S DISEASE

PROBLEM TO BE SOLVED: To provide novel high penetration compositions (HPCs) or high penetration prodrugs (HPPs) for treatment of Parkinson's disease. SOLUTION: The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after c

NOVEL HIGH PENETRATION DRUGS AND COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON'S DISEASE

PROBLEM TO BE SOLVED: To provide novel high penetration compositions (HPCs) or high penetration prodrugs (HPPs) for treatment of Parkinson's disease. SOLUTION: The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after c

Convenient synthesis of diaryliodonium salts for the production of [18F]F-DOPA

[18F]F-DOPA is an important radiotracer that is used in the diagnosis of Parkinson's disease and neuroendocrine tumours. We describe a simple synthesis for a number of diaryliodonium salt precursors that are suitable for the production of [18F]F-DOPA through reaction with no carrier added (n.c.a.) nucleophilic [18F]fluoride. The simple procedure gives bench-stable, complex iodonium precursors in good yields without the need for laborious anhydrous conditions. Further alteration to the precursor counterion can be readily achieved for a range of halides and pseudo halides by a simple modification of the workup. Preliminary "hot" and "cold" fluorination results show the suitability of the compounds for the production of [18F]F-DOPA.

NOVEL HIGH PENETRATION DRUGS AND THEIR COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON DISEASES

One aspect of the invention provides a composition of novel high penetration compositions (HPC) or a high penetration prodrug (HPP) for treatment of Parkinson's disease. The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolit

Fluorination of an arylboronic ester using [18F]selectfluor bis(triflate): Application to 6-[18F]fluoro-l-DOPA

The Ag-mediated electrophilic [18F]fluorination of an arylboronic ester is reported. This new radiochemical transformation uses [ 18F]selectfluor bis(triflate) in acetone. The process gave 6-[ 18F]fluoro-l-DOPA with a RCY of 19 ± 12% and a specific activity of 2.6 ± 0.3 GBq μmol-1.

Novel L-Dopa and dopamine prodrugs containing a 2-phenyl-imidazopyridine moiety

Purpose. The aim of this study was to gain insight into the feasibility of enhancing the delivery of L-Dopa and dopamine to the brain by linking these neurotransmitters and L-Dopa ethyl ester to 2-phenyl-3-carboxymethyl- imidazopyridine compounds giving r

Synthesis of the Chromophore of Pseudobactin, a Fluorescent Siderophore from Pseudomonas

Protected forms of dihydroxyphenylalanine (DOPA) were converted to the corresponding dihydroquinolin-2-ones 13 by nitration and reductive cyclization.Subsequent N-alkylation with α-halo-γ-aminobutyric acid derivatives provided the carbon framework 12 for the chromophore of pseudobactin.Conversion to protected forms of the fluorescent chromophore 5 was accomplished by reaction of 12 with Lawesson's reagent to produce the corresponding thioamide which was cyclized by reaction with mercuric acetate.